HIG Capital finalizes a strategic investment in the rise of pharmaceutical products
MIAMI – (COMMERCIAL THREAD(collectively, “Rising Pharmaceuticals†or the “Companyâ€), a leading supplier of generic and specialty pharmaceuticals in the United States.
Rising Pharmaceuticals develops and markets generic and specialty branded pharmaceuticals in various therapeutic categories. The Company uses a lightweight asset model with a fully outsourced third-party network, which provides robust capabilities across multiple dosage forms. With a diversified portfolio of over 125 products and the ability to rapidly commercialize complex molecules, Rising Pharmaceuticals is strategically positioned in the US pharmaceutical market. HIG has partnered with Vimal Kavuru, CEO of Rising Pharmaceuticals, to continue the company’s strong growth track record and support new initiatives, such as mergers and acquisitions and new product launches.
“We are delighted to partner with Vimal Kavuru and the exceptional leadership team at Rising Pharmaceutical,†said Mike Gallagher, Managing Director of HIG. a major opportunity in the broader US generic pharmaceutical industry, and the Company’s track record in identifying, developing and launching complex pharmaceutical products should create an exciting next chapter for Rising Pharmaceuticals.
“We are delighted to enter this new chapter of growth with HIG,†said Vimal Kavuru, Founder and CEO of Rising Pharmaceuticals. “We have built an exceptional business model, as evidenced by our strong growth, our exceptional customer service levels and the tremendous support from our customers and partners. We look forward to accelerating Rising Pharmaceutical’s growth trajectory with HIG, which brings significant experience and resources to the pharmaceutical industry. sector, while continuing to support our customers and suppliers with first-rate service.
HIG’s investment in Rising Pharmaceuticals represents its latest transaction in the pharmaceutical services industry. Other active investments in HIG’s pharmaceutical services include Aspire Pharma, BioVectra, Leiters and Taconic BioSciences.
About Rising Pharmaceuticals
Rising Pharmaceuticals and its subsidiaries is a supplier of generic and specialty brand pharmaceuticals. Rising focuses on development, regulatory and business aspects of the product lifecycle while outsourcing manufacturing to its network of over 23 strategic CMO and CDO partners. The Company is based in New Brunswick, New Jersey. For more information about the Company, please visit www.risingpharma.com.
About HIG Capital
HIG is a leading global alternative asset investment firm with over $ 45 billion in equity under management. * Based in Miami and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco , Atlanta and Stamford in the United States, as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, HIG specializes in providing debt and equity capital to small and medium-sized enterprises, using a / value-added approach:
|
1. |
HIG’s equity funds invest in company buyouts, recapitalizations and company spin-offs of both profitable and underperforming companies. |
|
|
|
|
2. |
HIG Debt Funds invest in senior, unitranche and junior debt financing to companies of all sizes, both on a primary basis (direct origination) as well as in secondary markets. HIG is also a primary manager of CLO, through its WhiteHorse family of vehicles, and operates a publicly traded BDC, WhiteHorse Finance. |
|
|
|
|
3. |
HIG’s real estate funds invest in value-added properties, which can benefit from improved asset management practices. |
|
|
|
|
4. |
HIG Infrastructure focuses on making value-added and core-plus investments in the infrastructure sector. |
Since its inception in 1993, HIG has invested and managed more than 300 companies around the world. The company’s current portfolio includes more than 100 companies with combined sales of over $ 30 billion. For more information, please visit HIG’s website at www.higcapital.com.
* Based on total capital commitments managed by HIG Capital and its subsidiaries.